Exane Derivatives’s Proofpoint, Inc. PFPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-9
| Closed | -$1.56K | – | 1091 |
|
|
2021
Q2 | $1.56K | Hold |
9
| – | – | ﹤0.01% | 836 |
|
|
2021
Q1 | $1.13K | Hold |
9
| – | – | ﹤0.01% | 720 |
|
|
2020
Q4 | $1.23K | Buy |
9
+2
| +29% | +$219 | ﹤0.01% | 663 |
|
|
2020
Q3 | $739 | Hold |
7
| – | – | ﹤0.01% | 646 |
|
|
2020
Q2 | $778 | Buy |
7
+1
| +17% | +$114 | ﹤0.01% | 572 |
|
|
2020
Q1 | $616 | Hold |
6
| – | – | ﹤0.01% | 572 |
|
|
2019
Q4 | $740 | Buy |
+6
| New | +$715 | ﹤0.01% | 573 |
|
|
2019
Q3 | – | Sell |
-6
| Closed | -$721 | – | 708 |
|
|
2019
Q2 | $721 | Sell |
6
-1
| -14% | -$118 | ﹤0.01% | 574 |
|
|
2019
Q1 | $850 | Buy |
7
+1
| +17% | +$110 | ﹤0.01% | 509 |
|
|
2018
Q4 | $503 | Hold |
6
| – | – | ﹤0.01% | 606 |
|
|
2018
Q3 | $635 | Sell |
6
-54
| -90% | -$6.28K | ﹤0.01% | 570 |
|
|
2018
Q2 | $6.9K | Sell |
60
-138
| -70% | -$16.8K | ﹤0.01% | 466 |
|
|
2018
Q1 | $22.1K | Sell |
198
-1,515
| -88% | -$161K | ﹤0.01% | 392 |
|
|
2017
Q4 | $152K | Buy |
1,713
+1,542
| +902% | +$140K | 0.03% | 258 |
|
|
2017
Q3 | $14.9K | Sell |
171
-15
| -8% | -$1.33K | ﹤0.01% | 368 |
|
|
2017
Q2 | $16.1K | Buy |
+186
| New | +$15.3K | ﹤0.01% | 372 |
|
Other funds holding PFPT
Exane Derivatives's PFPT Position: Q3 2021 in Review
Exane Derivatives sold out of Proofpoint, Inc. (PFPT) in Q3 2021, closing a stake of 9 shares — an estimated $1.56K sold.
Exane Derivatives first reported a position in PFPT in Q2 2017 and held it in 16 quarters. The position peaked at $152K in Q4 2017. 2 funds tracked by Wall St. Rank hold PFPT as of Q3 2021.
- Exane Derivatives reported no remaining Proofpoint, Inc. position as of Q3 2021 after selling out during the quarter.
- Exane Derivatives sold 9 Proofpoint, Inc. shares in Q3 2021, an estimated $1.56K.
- Exane Derivatives first reported a position in Proofpoint, Inc. in Q2 2017 and held it in 16 quarters.
- Exane Derivatives's Proofpoint, Inc. position peaked at $152K in Q4 2017.
- 2 funds tracked by Wall St. Rank held Proofpoint, Inc. as of Q3 2021.
Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.